Services

Histology

Pharmacology

Medical Device Testing

In Vitro Screening

Animal Model Development

Custom Assay Development

Vivarium Rental

Toxicology

Species

Non-human Primates

Dogs

Mini-pigs / Pigs

Rabbits

Mice

Rats

Sheep

Guinea Pigs

Hamsters

Other Species

Therapeutic Areas

Oncology

Immunology & Inflammation

Neurology / CNS

Cardiovascular

Dermatology & Wound Healing

Metabolism

Gastroenterology

Hepatology

Pulmonology

Infectious Diseases & Sepsis

Musculoskeletal

Nephrology & Urology

Capabilities

GLP / IND-Enabling Studies

Small and Large Animal Housing

Bioanalytical Platforms

About

News

Contact

Career

Request a Quote

Logo
☰
  • Services ⌄
    • Histology
    • Pharmacology
    • Medical Device Testing
    • In Vitro Screening
    • Animal Model Development
    • Custom Assay Development
    • Vivarium Rental
    • Toxicology
  • Species ⌄
    • Non-human Primates
    • Dogs
    • Mini-pigs / Pigs
    • Rabbits
    • Mice
    • Rats
    • Sheep
    • Guinea Pigs
    • Hamsters
    • Other Species
  • Therapeutic Areas ⌄
    • Oncology
    • Immunology & Inflammation
    • Neurology / CNS
    • Cardiovascular
    • Dermatology & Wound Healing
    • Metabolism
    • Gastroenterology
    • Hepatology
    • Pulmonology
    • Infectious Diseases & Sepsis
    • Musculoskeletal
    • Nephrology & Urology
  • Capabilities ⌄
    • GLP / IND-Enabling Studies
    • Small and Large Animal Housing
    • Bioanalytical Platforms
  • About ⌄
    • News
  • Contact ⌄
    • Career
    • Request a Quote

Medicare Pays Twice as Much as VA for Many Drugs, GAO Finds

  • Post author:Sam
  • Post published:January 18, 2021
  • Post category:Drug Industry Daily

Medicare Part D pays twice as much on average for hundreds of drugs as the Department of Veterans Affairs (VA), mostly because VA negotiates prices directly with drugmakers, the Government…

Continue ReadingMedicare Pays Twice as Much as VA for Many Drugs, GAO Finds

Most FDA Approved Novel Drugs in 2020 Went Through Accelerated Reviews

  • Post author:Sam
  • Post published:January 18, 2021
  • Post category:Drug Industry Daily

Most of the 53 novel drugs approved by the FDA in 2020 were reviewed through at least one expedited approval process, the agency said in a report on the year.…

Continue ReadingMost FDA Approved Novel Drugs in 2020 Went Through Accelerated Reviews

Trio of Drugmakers File Lawsuits Against HHS Over 340B Discounts

  • Post author:Sam
  • Post published:January 18, 2021
  • Post category:Drug Industry Daily

AstraZeneca (AZ), Sanofi and Eli Lilly have each filed lawsuits against HHS, arguing the federal government can’t force them to provide 340B drug discounts to contract pharmacies. Source: Drug Industry…

Continue ReadingTrio of Drugmakers File Lawsuits Against HHS Over 340B Discounts

HHS Issues Final Rule Imposing Renewable Term Limits for FDA Directors

  • Post author:Sam
  • Post published:January 18, 2021
  • Post category:Drug Industry Daily

Another last-minute Trump administration policy was issued at the end of last week by HHS that requires five-year, renewable term limits for directors of all agencies under the department, including…

Continue ReadingHHS Issues Final Rule Imposing Renewable Term Limits for FDA Directors

Moderna Will Evaluate Booster Shot for COVID-19 Vaccine in New Trial

  • Post author:Sam
  • Post published:January 18, 2021
  • Post category:Drug Industry Daily

Participants who received a full two-shot regimen in Moderna’s phase 1 vaccine trial are being given the option to receive a third booster shot through a new clinical trial in…

Continue ReadingModerna Will Evaluate Booster Shot for COVID-19 Vaccine in New Trial

David Kessler to Take Reins as Operation Warp Speed’s Scientific Leader

  • Post author:Sam
  • Post published:January 18, 2021
  • Post category:Drug Industry Daily

Former FDA Commissioner David Kessler is set to become Operation Warp Speed’s new chief science officer as just a single day remains until the Biden presidency takes up the mantle…

Continue ReadingDavid Kessler to Take Reins as Operation Warp Speed’s Scientific Leader

ITC Imposes 21-Month U.S. Ban on Botox Competitor, a Reduction From Initial Ban of 10 Years

  • Post author:Sam
  • Post published:December 17, 2020
  • Post category:Drug Industry Daily

The import, sale and marketing of a competitor to AbbVie’s Botox wrinkle treatment must be stopped for nearly two years, the U.S. International Trade Commission (ITC) ruled this week. Source:…

Continue ReadingITC Imposes 21-Month U.S. Ban on Botox Competitor, a Reduction From Initial Ban of 10 Years

COVID-19 Vaccine Developers Adjust Phase 3 Trial Protocols to Allow Authorized Vaccines

  • Post author:Sam
  • Post published:December 17, 2020
  • Post category:Drug Industry Daily

COVID-19 vaccine developers are faced with an ethical quandary — whether to let phase 3 trial participants become “unblinded” and to receive authorized vaccines as they become available, which could…

Continue ReadingCOVID-19 Vaccine Developers Adjust Phase 3 Trial Protocols to Allow Authorized Vaccines

GSK’s Benlysta Approved to Treat Active Lupus Nephritis

  • Post author:Sam
  • Post published:December 17, 2020
  • Post category:Drug Industry Daily

GlaxoSmithKline has received FDA approval for Benlysta (belimumab) to treat active lupus nephritis, a serious inflammation of the kidneys that appears in about four in 10 patients with the most…

Continue ReadingGSK’s Benlysta Approved to Treat Active Lupus Nephritis

FDA Advisory Panel Gives Big Thumbs Up for Moderna’s COVID-19 Vaccine

  • Post author:Sam
  • Post published:December 17, 2020
  • Post category:Drug Industry Daily

The FDA’s vaccines advisory committee voted almost unanimously on Thursday in favor of Emergency Use Authorization (EUA) for Moderna’s COVID-19 vaccine, with all but one abstaining member supporting clearance, and…

Continue ReadingFDA Advisory Panel Gives Big Thumbs Up for Moderna’s COVID-19 Vaccine
  • Go to the previous page
  • 1
  • …
  • 184
  • 185
  • 186
  • 187
  • 188
  • 189
  • 190
  • …
  • 385
  • Go to the next page

Stay Connected

Keep up with the latest news & insights.

Contact Us

Phone:
+1 858-605-5882
Fax:
+1 858-605-5916
Email:
info@biolegacyresearch.com
Mail:

6042 Cornerstone Court W

Suite E

San Diego, CA 92121

Social:
© 2025 BioLegacy Research. All rights reserved.